University of North Carolina CEMALB
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Peden, David
SmokeyT, NCT03444298: A Study of Gamma Tocopherol-enriched Supplement on Lower Airway Responses to Inhaled Wood Smoke in Healthy Adults

Completed
2
16
US
Gamma Tocopherol, Vitamin E, Placebo, Neutral oil
University of North Carolina, Chapel Hill, National Institute of Environmental Health Sciences (NIEHS)
Airway Inflammation, Asthma
03/23
03/23
NCT03556683: Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

Completed
N/A
22
US
3% Hypertonic Saline, 7% Hypertonic Saline
University of North Carolina, Chapel Hill, National Heart, Lung, and Blood Institute (NHLBI)
Moderate to Severe Asthma
06/24
06/24
NCT02767973: To Identify Persons Who Are Susceptible to WSP-induced Inflammation and Examine the Role of GSTM1 and Other Factors in This Susceptibility

Recruiting
N/A
160
US
Wood Smoke Particles (WSP)
University of North Carolina, Chapel Hill, National Institute of Environmental Health Sciences (NIEHS)
Airway Inflammation, Allergic Asthma
05/25
05/25
Hernandez, Michelle
iTREAT-PC, NCT06272370: Individualizing Treatment for Asthma in Primary Care

Recruiting
4
125
US
Asthma Symptom Monitoring online tools, Inhaled Steroids, Azithromycin Pill
DARTNet Institute, Penn State University, Icahn School of Medicine at Mount Sinai, University of Colorado, Denver, RAND, University of Washington, Rutgers University, University of North Carolina, Brigham and Women's Hospital, Reliant Medical Group, Kelsey Research Foundation, Wake Forest University Health Sciences
Asthma, Bronchial Diseases, Respiratory Tract Infections, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Immune System Diseases
06/24
09/24
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
01/25
01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
03/26
03/26
RAPID, NCT04287621: Registry of Asthma Patients Initiating DUPIXENT®

Active, not recruiting
N/A
718
Europe, Canada, Japan, US
DUPIXENT®, dupilumab, REGN668, SAR231893
Regeneron Pharmaceuticals, Sanofi
Asthma
07/26
07/26

Download Options